Rowell V, Rowell F J, Baker A, Laurie D, Sidki A M
Bull World Health Organ. 1988;66(2):211-7.
Reported is an enzyme-linked immunosorbent assay (ELISA) that has been optimized and validated for the determination of chloroquine in urine or dried blood spots. The assay employs antisera raised in sheep to a chloroquine derivative conjugated to keyhole limpet haemocyanin and chloroquine conjugated to porcine thyroglobulin adsorbed onto the wells of a microtitration plate. The competitive binding of the antiserum to the wells was monitored using an alkaline-phosphatase-conjugated second antibody and a specific substrate. The assay exhibits no cross-reactivity with known chloroquine metabolites, other antimalarials, and commonly used drugs. The method was used to determine chloroquine in dried blood spot extracts and urine from a patient who was receiving a prescribed prophylactic chloroquine regimen. The drug was detected in the urine for 17 weeks and in the dried blood spots for 4 weeks after termination of the therapy.
报道了一种酶联免疫吸附测定（ELISA）方法，该方法已针对尿液或干血斑中氯喹的测定进行了优化和验证。该测定法使用在绵羊体内产生的抗血清，该抗血清针对与钥孔戚血蓝蛋白偶联的氯喹衍生物以及吸附在微量滴定板孔上的与猪甲状腺球蛋白偶联的氯喹。使用碱性磷酸酶偶联的二抗和特异性底物监测抗血清与孔的竞争性结合。该测定法与已知的氯喹代谢物、其他抗疟药和常用药物无交叉反应。该方法用于测定接受规定预防性氯喹治疗方案的患者的干血斑提取物和尿液中的氯喹。治疗终止后，在尿液中检测到该药物达17周，在干血斑中检测到4周。
